News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
473,867 Results
Type
Article (25279)
Company Profile (172)
Press Release (448400)
Multimedia
Podcasts (122)
Webinars (17)
Section
Business (145562)
Career Advice (1337)
Deals (26102)
Drug Delivery (117)
Drug Development (55078)
Employer Resources (100)
FDA (10271)
Job Trends (11252)
News (243411)
Policy (23845)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (1397)
Accelerated approval (21)
Adcomms (29)
Allergies (99)
Alliances (38977)
ALS (100)
Alzheimer's disease (973)
Antibody-drug conjugate (ADC) (229)
Approvals (10445)
Artificial intelligence (383)
Autoimmune disease (94)
Automation (24)
Bankruptcy (238)
Best Places to Work (8571)
BIOSECURE Act (19)
Biosimilars (184)
Biotechnology (75)
Bladder cancer (96)
Brain cancer (36)
Breast cancer (351)
Cancer (2934)
Cardiovascular disease (285)
Career advice (1121)
Career pathing (28)
CAR-T (154)
CDC (43)
Celiac Disease (1)
Cell therapy (420)
Cervical cancer (23)
Clinical research (47863)
Collaboration (1275)
Company closure (2)
Compensation (768)
Complete response letters (53)
COVID-19 (1747)
CRISPR (61)
C-suite (661)
Cystic fibrosis (91)
Data (3843)
Decentralized trials (2)
Denatured (31)
Depression (105)
Diabetes (297)
Diagnostics (4339)
Digital health (30)
Diversity (12)
Diversity, equity & inclusion (26)
Drug discovery (196)
Drug pricing (213)
Drug shortages (34)
Duchenne muscular dystrophy (150)
Earnings (55622)
Editorial (54)
Employer branding (15)
Employer resources (95)
Events (67101)
Executive appointments (784)
FDA (12279)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (3)
Frontotemporal dementia (5)
Funding (862)
Gene editing (109)
Generative AI (35)
Gene therapy (337)
GLP-1 (873)
Government (3625)
Grass and pollen (7)
Guidances (296)
Healthcare (12288)
HIV (38)
Huntington's disease (24)
IgA nephropathy (60)
Immunology and inflammation (178)
Immuno-oncology (39)
Indications (82)
Infectious disease (1930)
Inflammatory bowel disease (137)
Inflation Reduction Act (14)
Influenza (74)
Intellectual property (160)
Interviews (198)
IPO (10750)
IRA (55)
Job creations (2931)
Job search strategy (960)
JPM (54)
Kidney cancer (10)
Labor market (69)
Layoffs (403)
Leadership (30)
Legal (5672)
Liver cancer (48)
Longevity (11)
Lung cancer (398)
Lymphoma (251)
Machine learning (26)
Management (36)
Manufacturing (675)
MASH (112)
Medical device (6421)
Medtech (6451)
Mergers & acquisitions (16123)
Metabolic disorders (965)
Multiple sclerosis (116)
NASH (20)
Neurodegenerative disease (189)
Neuropsychiatric disorders (75)
Neuroscience (1823)
Neurotech (1)
NextGen: Class of 2026 (4562)
Non-profit (2918)
Now hiring (48)
Obesity (537)
Opinion (256)
Ovarian cancer (78)
Pain (162)
Pancreatic cancer (119)
Parkinson's disease (185)
Partnered (25)
Patents (331)
Patient recruitment (277)
Peanut (27)
People (46080)
Pharmaceutical (81)
Pharmacy benefit managers (33)
Phase 1 (14926)
Phase 2 (20307)
Phase 3 (16279)
Pipeline (3663)
Policy (290)
Postmarket research (1774)
Preclinical (5379)
Press Release (70)
Prostate cancer (164)
Psychedelics (40)
Radiopharmaceuticals (209)
Rare diseases (585)
Real estate (4816)
Recruiting (42)
Regulatory (17656)
Reports (28)
Research institute (1335)
Resumes & cover letters (211)
Rett syndrome (6)
RNA editing (12)
RSV (52)
Schizophrenia (134)
Series A (138)
Series B (102)
Service/supplier (17)
Sickle cell disease (73)
Special edition (23)
Spinal muscular atrophy (125)
Sponsored (27)
Startups (2524)
State (2)
Stomach cancer (12)
Supply chain (94)
Tariffs (97)
The Weekly (89)
Vaccines (590)
Venture capital (73)
Weight loss (391)
Women's health (57)
Worklife (12)
Date
Today (57)
Last 7 days (363)
Last 30 days (1380)
Last 365 days (19555)
2026 (1947)
2025 (19841)
2024 (23132)
2023 (26053)
2022 (34790)
2021 (37284)
2020 (36951)
2019 (33181)
2018 (25475)
2017 (22728)
2016 (21711)
2015 (24934)
2014 (19367)
2013 (16396)
2012 (17758)
2011 (18357)
2010 (16660)
Location
Africa (549)
Alabama (49)
Alaska (5)
Arizona (157)
Arkansas (10)
Asia (30820)
Australia (4080)
California (6227)
Canada (2529)
China (826)
Colorado (318)
Connecticut (294)
Delaware (231)
Europe (66180)
Florida (1044)
Georgia (173)
Hawaii (3)
Idaho (36)
Illinois (646)
India (56)
Indiana (380)
Iowa (11)
Japan (347)
Kansas (99)
Kentucky (34)
Louisiana (19)
Maine (29)
Maryland (936)
Massachusetts (4719)
Michigan (178)
Minnesota (347)
Mississippi (4)
Missouri (66)
Montana (20)
Nebraska (19)
Nevada (59)
New Hampshire (33)
New Jersey (2302)
New Mexico (24)
New York (1642)
North Carolina (1048)
North Dakota (6)
Northern California (2883)
Ohio (228)
Oklahoma (15)
Oregon (29)
Pennsylvania (1512)
Puerto Rico (19)
Rhode Island (33)
South America (813)
South Carolina (18)
Southern California (2595)
Tennessee (111)
Texas (1043)
United States (24230)
Utah (141)
Vermont (1)
Virginia (215)
Washington D.C. (74)
Washington State (499)
West Virginia (4)
Wisconsin (82)
Wyoming (1)
473,867 Results for "johnson matthey pharma services".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Psychedelics
AbbVie CSO Touts ‘Breakthrough Type Therapy’ Psychedelic as J&J’s Spravato Keeps Growing
Sales of Johnson & Johnson’s esketamine-based nasal spray jumped in the fourth quarter last year, priming the pump for a suite of other pharmas, including AbbVie, champing at the bit with their own psychedelics.
February 6, 2026
·
2 min read
·
Dan Samorodnitsky
Manufacturing
Big Pharma Pushes FDA To Decouple Inspections From Drug Approval Applications
Representatives of companies including AbbVie, Eli Lilly, Johnson & Johnson and Merck have voiced concerns about the FDA’s approach to pre-approval inspections.
December 16, 2025
·
4 min read
·
Nick Paul Taylor
Press Releases
Pharmaceutical Service Provider Vetter Pharma to Build New Manufacturing Site in Germany
Strategic Investments in the EU and US strengthen Vetter’s Global Footprint • Building permit application for German site submitted • Construction start is scheduled for the 2nd quarter 2026, with operational readiness in 2031 • Expansions in the US and Europe are included in a €1.5 billion investment plan
January 29, 2026
·
1 min read
Press Releases
Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium
February 9, 2026
·
10 min read
Press Releases
Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference
February 3, 2026
·
1 min read
Press Releases
Johnson & Johnson reports Q4 and Full-Year 2025 results
January 21, 2026
·
20 min read
Johnson Matthey signs agreement to sell its Medical Device Components business for US$700m
Johnson Matthey Plc (JM) announces that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.
March 20, 2024
·
4 min read
Press Releases
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026
January 5, 2026
·
1 min read
Press Releases
Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting
January 13, 2026
·
27 min read
Press Releases
As mental health patients turn to AI chatbots, how can pharma lead the way?
A new report by Bryter released today reveals where pharma can lead as patients turn to (and question) AI tools for mental health.
February 5, 2026
·
1 min read
1 of 47,387
Next
